Analyst Commenthttps://www.bnn.ca/video/gerard-ferguson-discusses-concordia-international~927242
2016-08-09 COMMENT Gerard Ferguson
This fell into some of the issues that Valeant (VRX-N) was facing in the US. Aggressive pricing for a lot of critical drugs. They did the right thing by diversifying out of the US marketplace and into Europe. Timing couldn’t have been worse with the timing of BREXIT. They are going through a strategic review process right now. The fact that it has been drawn out this long suggests there is a lack of buyers. This is a “wait and see” type of stock. Heavy debt.
Login to show your approval Login to show your disapproval / Be the first to comment
Price:
$22.300
Subject:
CANADIAN
Bias:
OPTIMISTIC
Owned:
Unknown